Guggenheim analyst Seamus Fernandez raised the firm’s price target on Cidara Therapeutics (CDTX) to $167 from $70 and keeps a Buy rating on the shares. FDA end-of-Phase 2 feedback exceeded the firm’s expectations, with the ANCHOR Phase 3 study population now broadened and expected to start dosing before the end of this month, the analyst tells investors. The firm would characterize the FDA discussion as “strong support and validation,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara announced several positive CD388 updates, says H.C. Wainwright
- Cidara Therapeutics price target raised to $137 from $115 at RBC Capital
- Cidara Therapeutics announces expanded, accelerated Phase 3 plan for CD388
- Cidara Therapeutics price target raised to $123 from $45 at WBB Securities
- Cidara Therapeutics presents data on CD388 from Phase 2b NAVIGATE trial